# Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

> **NCT01442376** · PHASE3 · COMPLETED · sponsor: **Helsinn Healthcare SA** · enrollment: 502 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting

## Interventions

- **DRUG:** Palonosetron
- **DRUG:** Palonosetron
- **DRUG:** Ondansetron
- **DRUG:** Placebo to Ondansetron
- **DRUG:** Placebo to Ondansetron
- **DRUG:** Placebo to Palonosetron

## Key facts

- **NCT ID:** NCT01442376
- **Lead sponsor:** Helsinn Healthcare SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-10
- **Final completion:** 2012-11
- **Target enrollment:** 502 (ACTUAL)
- **Last updated:** 2014-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01442376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01442376, "Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01442376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*